utetium-177 hydroxyapatite: a promising agent for treatment of long standing inflammatory knee arthritis
- Conditions
- Health Condition 1: M658- Other synovitis and tenosynovitis
- Registration Number
- CTRI/2022/04/041884
- Lead Sponsor
- AIIMS Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients with refractory chronic inflammatory arthritis of the knee joint with evidence of inflammation on bone scan.
2.Patients diagnosed with rheumatoid arthritis that are unresponsive to conventional medical treatment (NSAIDs, DMARDs, and/or biologicals) for at least 6 months, with predominant knee joint involvement.
3.Patients diagnosed with osteoarthritis unresponsive to conventional medical treatment (NSAIDs) for at least 6 months.
4.Patients suffering from hemophilia with at least 2 hemarthrosis of the knee joint in the past 6 months despite use of coagulation factors.
1.Pregnant or breastfeeding women
2.Women planning to get pregnant within the next 6 months
3.Children < 6 years of age
4.Local skin infection at the injection site
5.Suspected septic arthritis
6.Intra-articular fracture
7.Ruptured popliteal cyst
8.Severe joint instability due to bone destruction
9.Patients who have undergone arthroscopy or surgery of the affected knee joint within the past 6 weeks
10.Patients who have received radiosynovectomy for the involved knee joint within the last 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate pain relief in patients receiving Lutetium-177 hydroxyapatite radiosynovectomy using Visual Analogue ScaleTimepoint: At 4 weeks and 12 weeks after radiosynovectomy
- Secondary Outcome Measures
Name Time Method To assess improvement in signs of joint inflammation by bone scanTimepoint: Prior to radiosynovectomy, and at 12 weeks after radiosynovectomy;To compare the knee joint tenderness, analgesic use and mobility <br/ ><br> <br/ ><br>Timepoint: Prior to radiosynovectomy, and at 4 weeks and 12 weeks after radiosynovectomy;To evaluate the improvement in daily functioning using Oxford knee scoreTimepoint: Prior to radiosynovectomy, and at 12 weeks after radiosynovectomy